Iconic Therapeutics is a biopharmaceutical company founded in 2002 with a primary focus on developing and commercializing immunoconjugate proteins. The company's proprietary recombinant protein, hI-con1, holds exclusive rights to Yale University patents and has shown promising potential in targeting and eliminating invader cells. Specifically, the protein binds to tissue factor (TF), activating natural killer cells to selectively attack pathologic neovascular blood vessels, including those associated with choroidal neovascularization (CNV) in wet age-related macular degeneration and TF-expressing cancer cells. Additionally, hI-con1 has demonstrated the ability to disrupt the positive feedback mechanism between TF and vascular endothelial growth factor (VEGF), thus potentially lowering VEGF levels. Phase 1 studies have shown no dose-limited toxicities and provided evidence of dose-related biological activity.
The last known investment in Iconic Therapeutics was a $4.11M Venture Round led by a group of investors including HBM Healthcare Investments, H.I.G. BioHealth Partners, MPM Capital, Elm Street Ventures, HBM Partners, Lundbeckfonden Ventures, OUP (Osage University Partners), JLABS, Georgia Venture Partners, and Diem Bioventures on 15 June 2018.
Iconic Therapeutics operates within the Biopharma, Biotechnology, and Health and Wellness industries, emphasizing the development of innovative immunoconjugate proteins to empower the immune system in targeting and eliminating invader cells, with a particular focus on addressing CNV and cancer.
